IL6 and metabolic syndrome: The resulting dyslipidemia and accumulation of LDLs can, in turn, induce inflammasome activation and the release of pro-inflammatory cytokines such as IL-1 and IL-6, promoting a systemic inflammatory state that could drive the pathophysiology of both dyslipidemia and steatotic liver disease [38,39].